Philips Respironics Halts U.S. Sales of Sleep Apnea Machines Amid Safety Concerns

Company Faces $400 Million in Costs and Hundreds of Lawsuits Following Recall of Over 5 Million Breathing Devices

Philips Respironics has agreed to halt sales of its sleep apnea machines in the U.S. following a series of recalls over safety concerns.
The Dutch manufacturer has recalled more than 5 million pressurized breathing machines due to risks that their internal foam can break down over time, leading users to inhale tiny particles and fumes while they sleep.
The company has reached a tentative agreement with the U.S. Food and Drug Administration (FDA) and the Department of Justice, which could cost the company nearly $400 million.
Philips will continue servicing previously sold machines in the U.S., but cannot sell new ones until it meets corrective actions laid out by the FDA.
675 personal injury lawsuits have been filed against Philips over the recalled devices, with customers reporting delays in trying to obtain refunds or new or refurbished machines.